文献速递主动脉疾病

胸主动脉腔内修复术后晚期内移植物移位:系统评价与荟萃分析

Late Endograft Migration After Thoracic Endovascular Aortic Repair: A Systematic Review and Meta-analysis.
PubMed 文献 · J Endovasc Ther · 2022-07-12

该系统评价与荟萃分析纳入7项前瞻性非随机研究和4项回顾性研究共1783例患者,合并内移植物移位发生率为4%(95%CI 2%-7%;范围0.2%-11%;I²=82%),移位相关并发症发生率31%(95%CI 12%-59%),再干预率32%(95%CI 15%-56%),移位相关死亡率5%(95%CI 1%-21%)。作者认为胸主动脉腔内修复术后密切标准化监测对早期发现移位和预防其后果至关重要。

要点

  • 胸主动脉腔内修复术后内移植物移位合并发生率为4%(95%CI 2%-7%;I²=82%)。
  • 移位相关并发症发生率31%(95%CI 12%-59%)、再干预率32%(95%CI 15%-56%)、死亡率5%(95%CI 1%-21%)。
  • 作者认为术后密切标准化监测对早期发现移位和预防其后果至关重要。

核心结论

  • 该荟萃分析首次提供胸主动脉腔内修复术后内移植物移位的合并参考估计值,结果有助于进一步刻画移位特征。
  • 移位与高比例内漏相关并发症、再干预和死亡相关,凸显其临床意义。
  • 作者认为胸主动脉腔内修复术后密切标准化监测对早期发现移位和预防其后果至关重要。

研究设计与样本

  • 系统电子检索MEDLINE(通过PubMed)、Web of Science和Cochrane对照试验中心注册库。
  • 纳入7项前瞻性非随机研究和4项回顾性研究,共1783例患者,其中70例发生内移植物移位。
  • 采用逆方差法进行结局的合并合成。

主要发现

  • 内移植物移位合并发生率为4%(95%CI 2%-7%;范围0.2%-11%;I²=82%)。
  • 合并并发症发生率为31%(95%CI 12%-59%;范围0%-100%;I²=64%)。
  • 合并再干预率为32%(95%CI 15%-56%;范围0%-100%;I²=55%)。
  • 内移植物移位所致合并死亡率为5%(95%CI 1%-21%;范围0%-40%;I²=24%)。

临床怎么用

  • 作者认为胸主动脉腔内修复术后密切标准化监测对早期发现内移植物移位和预防其后果至关重要。

局限性

  • 内移植物移位合并发生率异质性I²=82%。
  • 合并并发症发生率异质性I²=64%。
  • 合并再干预率异质性I²=55%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The objective of this systematic review was to report the cumulative incidence of endograft migration (EM), as well as the morbidity, reintervention rates, and mortality related to EM. This study aimed to provide evidence-based data on patient-relevant sequelae of EM after thoracic endovascular aortic repair (TEVAR) performed using contemporary aortic endografts. MATERIALS AND METHODS: A systematic electronic search of literature in MEDLINE (via PubMed), Web of Science, and Cochrane Central Register of Controlled Trials was performed. The pooled synthesis of outcomes was performed using the inverse variance method. RESULTS: Seven prospective non-randomized and 4 retrospective studies, including a total of 1783 patients presenting 70 EMs, were considered for the quantitative analysis. The pooled rate of EM was 4% (95% CI, 2%-7%; range, 0.2%-11%; I2=82%); pooled morbidity rate was 31% (95% CI, 12%-59%; range, 0%-100%; I2=64%) and pooled reintervention rate was 32% (95% CI, 15%-56%; range, 0%-100%; I2=55%). The pooled mortality rate due to EM was 5% (95% CI, 1%-21%; range, 0%-40%; I2=24%). CONCLUSION: For the first time, this meta-analysis provides pooled reference estimates of EM after TEVAR. Thus, the results hold the potential to further characterize EM after TEVAR. The clinical relevance of EM is underlined by its association with high rates of endoleak-related morbidity, reintervention, and mortality. Close standardized surveillance after TEVAR for early detection of EM and prophylaxis of its sequelae is essential.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Skrypnik D, Kalmykov E, Bischoff MS, et al. Late Endograft Migration After Thoracic Endovascular Aortic Repair: A Systematic Review and Meta-analysis. J Endovasc Ther. 2022. PMID: 35822261. doi:10.1177/15266028221109455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。